Eli Lilly and Co. is more than 15 years late to the game in the world of diabetes drugs. And it isn’t bringing much that doctors and patients haven’t already seen. Still, that might be good enough to make a few billion a year.
The head of the state Family and Social Services Administration said Tuesday that the federal government is expected to approve an extension of the Healthy Indiana Plan, but a request to use the plan for an Indiana Medicaid expansion could take much longer.
A patent held by J&J’s Janssen Alzheimer Immunotherapy Research & Development unit isn’t valid, Judge Richard Arnold said in a ruling in London Tuesday.
Indiana consumers are set to receive rebates that are 59 percent larger this year as Obamacare continues to force health insurers to refund premiums that exceed actual medical claims by more than 20 percent.
With recent attention focused on hospital prices, WellPoint and its peers have been enjoying a nice break from their long-running status as Public Enemy No. 1 in the nation’s health care debate. They shouldn’t expect it to last.
The nation’s largest pension fund worked with the Indianapolis-based health insurer to cut medical costs 19 percent by capping the price of some surgeries, in the latest sign payers are taking a tougher line against rising hospital claims.
Lilly’s drug, if approved, may be a significant competitor to Novo Nordisk A/S’s Victoza, which generated $1.64 billion in 2012.
The federal health care overhaul is expected to exacerbate problems regarding access to care in rural Indiana communities where is there is already a shortage of doctors and other health care providers.
The founder and CEO of Diagnotes Inc. thinks his company’s mobile app can help doctors run their office from their iPhones—just as many other professionals have been doing for years.
The biotech and technology companies could see their Marion County tax abatements reduced or cancelled if officials decide they didn’t fulfill promises on new investment and hiring.
Local providers will increasingly look for help from IT firms like Indigo Biosystems Inc. and VoCare Inc. as part of a coming wave of health IT innovation that is likely to mirror the IT revolution that began 30 years ago.
Eli Lilly and Co.’s injectable form of the antipsychotic Zyprexa is being investigated by U.S. regulators after two patients died three to four days after receiving the drug.
Drug companies like Eli Lilly and Co. can be sued for paying rivals to delay low-cost versions of popular medicines, the U.S. Supreme Court said in a decision that rewrites the rules governing the release of generic drugs.
A federal lawsuit says Indiana's social services agency has made changes to Medicaid waiver programs that threaten to deprive thousands of developmentally disabled people of income they need to survive outside of institutions.
The failures raise pressure on Lilly’s experimental diabetes and cancer drugs to make it to market to offset looming patent expirations.
A new recommendation from the Medicare Payment Advisory Commission, if enacted, would likely end one of the ways Indianapolis-area hospitals have generated healthy revenue from their recent spree of physician acquisitions.
Eli Lilly and Co. will pay Canadian drug developer Transition Therapeutics Inc. at least $7 million and up to as much as $247 million to take over the development of a potential diabetes treatment.
Indiana drivers who have to show proof of insurance to police after an accident or traffic violation can do so electronically starting July 1 under a new law that signals an increasing use of technology in insurance laws.
To get control of health care spending, prominent health policy wonks are calling for new rules requiring hospitals and insurers to raise the ‘veil of secrecy’ they have thrown over their prices for decades.
The trial ended after participants showed abnormal liver biochemistry, the Indianapolis-based drugmaker said Thursday in a statement.
